The patent describes the extraction and standardization of secure doses of psychedelic compounds
The Company additionally studies first quarter 2022 monetary outcomes and operational highlights
VANCOUVER, BC, May 17, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage pure psychedelic drug improvement firm, right now introduced that it has been issued a second patent by the United States Patent and Trademark Office (USPTO) for the extraction and standardization of pure psilocybin and related psychedelic compounds. The patent describes important know-how for remodeling variable psychedelic uncooked supplies into pharmaceutical-grade, standardized drug candidates.
“The issuance of Filament’s first US patent is a testament to the strength of our drug development platform,” mentioned Benjamin Lightburn, Chief Executive Officer. “This approval represents important progress for our intellectual property portfolio.”
Filament has developed progressive know-how to extract and standardize secure doses of pure compounds from magic mushrooms. The Company at the moment holds 5 patents, together with the first-ever patent for the extraction and standardization of pure psilocybin, which was issued on August 3, 2021.
First Quarter Financial Results and Operational Highlights
Filament launched its first quarter monetary outcomes and operational highlights for the interval ended March 31, 2022. Financial outcomes and operational highlights from the Company’s first quarter of 2022 and subsequent interval embrace:
- Cash and money equivalents of over $3.6 million;
- Issued patents by the Canadian Intellectual Property Office and the United States Patent and Trademark Office patents for the extraction and standardization of pure psilocybin;
- Held a pre-investigational new drug software assembly with the United States Food and Drug Administration discussing Filament’s pure psychedelic drug candidates, drug improvement technique and long-term plans;
- Entered right into a licensing settlement with Cybin Therapeutics to license and supply Filament’s proprietary botanical drug candidate, PEX010 (25mg), for 2 Phase II medical trials with, certainly one of which has acquired Health Canada authorization;
- Entered right into a licensing settlement with ATMA Journey Centers to supply PEX010 (25mg) to be used in a Phase I security trial, for which ATMA has acquired Health Canada authorization;
- Entered right into a licensing settlement with Psyence Group Inc. to supply PEX010 (25mg) and the related mental property to be used in Psyence’s upcoming medical trials within the United Kingdom.
ABOUT FILAMENT HEALTH (OTCQB:FLHLF) (NEO:FH) (FSE:7QS)
Filament Health is a clinical-stage pure psychedelic drug improvement firm. We consider that protected, standardized, naturally-derived psychedelic medicines can enhance the lives of many, and our mission is to see them within the fingers of everybody who wants them as quickly as attainable. Filament’s platform of proprietary mental property permits the invention, improvement, and supply of pure psychedelic medicines for medical improvement. We are paving the way in which with the first-ever pure psychedelic drug candidates.
Learn extra at www.filament.well being and on Twitter, Instagram and LinkedIn.
FORWARD LOOKING INFORMATION
Certain statements and data contained herein might represent “forward-looking statements” and “forward-looking information,” respectively, underneath Canadian securities laws. Generally, forward-looking data might be recognized by way of forward-looking terminology reminiscent of, “expect”, “anticipate”, “continue”, “estimate”, “may”, “will”, “should”, “believe”, “intends”, “forecast”, “plans”, “guidance” and related expressions are supposed to determine forward-looking statements or data. The forward-looking statements are usually not historic information, however mirror the present expectations of administration of Filament concerning future outcomes or occasions and are primarily based on data at the moment accessible to them. Certain materials components and assumptions have been utilized in offering these forward-looking statements. The forward-looking statements mentioned on this press launch might embrace, however are usually not restricted to, data in regards to the impression of the patent on the Company’s enterprise and the power of the Company to safe future patents. Forward-looking statements concerning the Company are primarily based on the Company’s estimates and are topic to identified and unknown dangers, uncertainties and different components that will trigger the precise outcomes, ranges of exercise, efficiency or achievements of Filament to be materially totally different from these expressed or implied by such forward-looking statements or forward-looking data, together with standing of patent functions and the power to safe patents. There might be no assurance that such statements will show to be correct, as precise outcomes and future occasions might differ materially from these anticipated in such statements. Accordingly, readers shouldn’t place undue reliance on forward-looking statements and forward-looking data. Filament is not going to replace any forward-looking statements or forward-looking data which are integrated by reference herein, besides as required by relevant securities legal guidelines.
SOURCE Filament Health Corp.
For additional data: MEDIA RELATIONS: Anna Cordon, Director of Communications, 778.245.9067, [email protected]; INVESTOR RELATIONS: KCSA Strategic Communications, Adam Holdsworth, 347.487.6788, [email protected]
FILAMENT HEALTH IS ISSUED SECOND PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE AND REPORTS Q1 RESULTS & More Latest News Update
FILAMENT HEALTH IS ISSUED SECOND PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE AND REPORTS Q1 RESULTS & More Live News
All this information that I’ve made and shared for you folks, you’ll prefer it very a lot and in it we hold bringing matters for you folks like each time so that you simply hold getting information data like trending matters and also you It is our purpose to have the ability to get
every kind of reports with out going by us in order that we will attain you the newest and greatest information free of charge in an effort to transfer forward additional by getting the knowledge of that information along with you. Later on, we are going to proceed
to offer details about extra today world news update kinds of newest information by posts on our web site so that you simply all the time hold shifting ahead in that information and no matter sort of data might be there, it would undoubtedly be conveyed to you folks.
FILAMENT HEALTH IS ISSUED SECOND PATENT BY UNITED STATES PATENT AND TRADEMARK OFFICE AND REPORTS Q1 RESULTS & More News Today
All this information that I’ve introduced as much as you or would be the most totally different and greatest information that you simply persons are not going to get anyplace, together with the knowledge Trending News, Breaking News, Health News, Science News, Sports News, Entertainment News, Technology News, Business News, World News of this information, you may get different kinds of information alongside together with your nation and metropolis. You will be capable of get data associated to, in addition to it is possible for you to to get details about what’s going on round you thru us free of charge
in an effort to make your self a educated by getting full details about your nation and state and details about information. Whatever is being given by us, I’ve tried to convey it to you thru different web sites, which you’ll like
very a lot and in case you like all this information, then undoubtedly round you. Along with the folks of India, hold sharing such information essential to your family members, let all of the information affect them they usually can transfer ahead two steps additional.
Credit Goes To News Website – This Original Content Owner News Website . This Is Not My Content So If You Want To Read Original Content You Can Follow Below Links